Seaport Therapeutics

Drug development in neuropsychiatry is marked by both tremendous promise and challenges, as highlighted by David Wainer in the The Wall Street Journal. Steven Paul comments on why some players in big pharma are reentering the arena after stepping away. Mentions Bristol Myers Squibb #Cobenfy, Intercept/JnJ, Abbvie/Cerevel, and emerging companies including Seaport Therapeutics https://lnkd.in/eiai_e8q

We’re pleased to welcome Bob Hombach to our Board of Directors and as the Chair of our Audit Committee. He is the former Chief Financial Officer at Baxter (NYSE: BAX), an ~$18 billion company, as well as Baxalta (NYSE: BXLT), a $6 billion company, prior to its acquisition by Shire in 2016. His three decades of experience also includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of Directors, such as FORTUNE 500 companies like BioMarin (NASDAQ: BMRN), where he also chairs the Audit Committee, and Henry Schein (NASDAQ: HSIC), a member of the S&P 500® index. Read the press release: https://bit.ly/4iDs08j

We’re pleased to share details of our participation in upcoming investor conferences in March. Our Seaport management team was invited to participate in the Leerink Partners Global Healthcare Conference 2025 in Miami, FL from March 10-12th, and will present at the Stifel 2025 Virtual CNS Forum on March 19th at 2:00pm EDT. More details: https://bit.ly/3QGAU97

Our team was at the International Society for CNS Clinical Trials and Methodology (ISCTM) Conference this week to present a new meta-analysis exploring the impact of clinical trial design factors on the magnitude of placebo response in major depressive disorder (#MDD) clinical trials. In the meta-analysis, a key finding was that the number and frequency of clinician-administered assessments in major depressive disorder (#MDD) trials were positively correlated with an increased placebo response. Learn more about the meta-analysis in today’s press release: https://bit.ly/3Qsz8bx View the poster: https://bit.ly/4k9dpmE

We’re pleased to share new research published in Molecular Pharmaceutics showcasing our Glyph platform’s unique ability to enhance drug transport through the lymphatic system for increased therapeutic exposure. The study, conducted by the Monash Institute of Pharmaceutical Sciences (MIPS) in collaboration with Seaport Therapeutics, evaluated ways of modifying mycophenolic acid (MPA), an immunomodulatory drug, to improve its absorption through the lymphatic system and increase its concentration in lymph nodes. In the study, a newly examined phenol attachment point showed the highest lymphatic transport of MPA reported to date – approximately 55 percent – and up to two-fold higher release in lymph nodes compared to the previously reported acid attachment point.   The research demonstrated the impact of linker characteristics on the extent of lymphatic transport and release in the lymph nodes. Overall, this builds on the prior evidence supporting the versality of the Glyph platform and reinforces the innovation behind our prodrug chemistry technology. Read the press release: https://bit.ly/4hy4pG5 Access the paper: https://bit.ly/418PGvs See Glyph in action:

We’re delighted to be named one of the 25 Startups to Watch in 2025 by Boston Business Journal! Being recognized as a company “on the verge of something big” fuels our commitment to changing the lives of patients and their families dealing with depression and anxiety – two of the most disabling neuropsychiatric disorders.   View the full list, which includes companies across different industries: https://lnkd.in/d5GscFaR

Seaport team members, Daniel Bonner, Co-founder and Senior Vice President, Platform, and Jamie Simpson, Co-inventor of Glyph Technology and Head of Chemistry, were on the floor at the Medicinal & Bioorganic Chemistry Foundation (MBCF) 2025 in Steamboat Springs, Colorado this week to present the translation across preclinical species to pharmacokinetic and pharmacodynamic data in a Phase 1 study with our clinical-stage therapeutic candidate, SPT-300, an oral prodrug of allopregnanolone. The presented data demonstrate enhanced oral bioavailability of SPT-300 and validate the ability of our Glyph platform to design new drug candidates with human drug exposure from a set of tailored preclinical assays. #MBCF2025 View the full poster: https://lnkd.in/ekWJ_CWq

Seaport Therapeutics is seeking a talented and entrepreneurial Program Leader (PL) to quarterback the SPT-300 program within Seaport, with the potential to make an impact on patients globally. This is a high-profile role working directly with our CEO Daphne Zohar and the executive team. Check out this exciting opportunity to join the Seaport team! https://lnkd.in/ewUPJ8iD

Congratulations to our Co-founder and Board Chair, Steven Paul, M.D., for being recognized on the Brain & Behavior Research Foundation (BBRF)’s list of 2024 Leading Research Achievements for scientific work published in JAMA Psychiatry and The Lancet Group. The featured research demonstrated that KarXT (now Cobenfy) – a new medicine for treating schizophrenia – was successful in two phase 3 clinical trials reported in 2024 that contributed to the drug’s approval by the FDA. We are pleased to honor Steve’s scientific work that led to the advancement of KarXT/Cobenfy and appreciate his continued contributions to the advancement of important neuropsychiatric medicines, including Seaport’s pipeline focused on depression and anxiety, which are among the most disabling of all neuropsychiatric disorders. Read more about the full list of BBRF’s leading research: https://lnkd.in/esTRunAy

Congratulations to our Co-founder and Board Chair, Steven Paul, M.D., for being recognized on the Brain & Behavior Research Foundation (BBRF)’s list of 2024 Leading Research Achievements for scientific work published in JAMA Psychiatry and The Lancet Group. The featured research demonstrated that KarXT (now Cobenfy) – a new medicine for treating schizophrenia – was successful in two phase 3 clinical trials reported in 2024 that contributed to the drug’s approval by the FDA. We are pleased to honor Steve’s scientific work that led to the advancement of KarXT/Cobenfy and appreciate his continued contributions to the advancement of important neuropsychiatric medicines, including Seaport’s pipeline focused on depression and anxiety, which are among the most disabling of all neuropsychiatric disorders. Read more about the full list of BBRF’s leading research: https://lnkd.in/esTRunAy